Cameron Owen
Co-Founder of rBIO
Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.
rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.
Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.
- Biology
- Pharmaceutical
- Entrepreneur
- ðSan Diego, CA
read more
 
BOOK NOW FOR your podcast
Cameron Owen
Co-Founder of rBIO
- Biology
- Pharmaceutical
- Entrepreneur
- ðSan Diego, CA
Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.
rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.
Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.
read more
BOOK NOW FOR your podcast
Cameron Owen
Co-Founder of rBIO
- ðSan Diego, CA
- Biology
- Pharmaceutical
- Entrepreneur
Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.
rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.
Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.
read more
As seen on
rBIO, a US-based early-stage synthetic biology company, achieved its first in-lab milestone in December 2020 when it was able to synthetically produce human insulin using its recombinant DNA (rDNA) model and process. The company can achieve upscale production of insulin, potentially lowering the cost of the drug by 30%, as well as identify other prescription drugs that can be manufactured by manipulating microorganisms to express peptide hormones.
rBIOÂ launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.
Ask me
| What's the plan for having pharma supply chains here on domestic soil? |
| What's the importance of having those chains here in USA? |
| What are you doing differently than everyone else? |
| What are the results you've seen in the lab? |
| How has covid affected your business/future plans for business? |
